| ISIN | LU3028243478 |
|---|---|
| Valorennummer | 143765335 |
| Bloomberg Global ID | CLOEUC SW |
| Fondsname | UBS (Lux) Fund Solutions - UBS EUR AAA CLO UCITS ETF hCHF acc |
| Fondsanbieter |
UBS Asset Management Switzerland AG, Zurich
8098 Zürich, Schweiz E-Mail: ubs-am-wholesale-switzerland@ubs.com Web: www.ubs.com/fonds |
| Fondsanbieter | UBS Asset Management Switzerland AG, Zurich |
| Vertreter in der Schweiz |
UBS Fund Management (Switzerland) AG Basel Telefon: +41 61 288 49 10 |
| Distributor(en) | |
| Anlagekategorie | Aktienfonds |
| EFC-Kategorie | Asset-backed Securities |
| Anteilskategorie | Accumulation |
| Domizilland | Luxemburg |
| Konditionen bei der Ausgabe | keine Ausgabekommission und/oder Gebühren zugunsten des Fonds (Ausgabe erfolgt zum Inventarwert) |
| Konditionen bei der Rücknahme | Keine Rücknahmekommission und/oder Gebühren zugunsten des Fonds (Rücknahme erfolgt zum Inventarwert) |
| Investment-Strategie *** | The UBS EUR AAA CLO UCITS ETF sub-fund aims to provide investors with a total return, taking into account both capital appreciation and income returns by investing predominantly in AAA-rated collateralized loan obligations. This sub-fund is actively managed and uses the J.P. Morgan European Collateralized Loan Obligation AAA Index (Net Total Return) as a reference for portfolio construction, performance comparison and risk management but is not constrained by it. The majority of the sub-fund’s securities will be components of the benchmark. |
| Besonderheiten |
| Aktueller Preis * | 10.03 CHF | 23.10.2025 |
|---|---|---|
| Vorheriger Preis * | 10.03 CHF | 22.10.2025 |
| 52 Wochen Hoch * | 10.04 CHF | 13.10.2025 |
| 52 Wochen Tief * | 10.00 CHF | 11.08.2025 |
| NAV * | 10.03 CHF | 23.10.2025 |
| Ausgabepreis * | ||
| Rücknahmepreis * | ||
| Schlusskurs * | ||
| Indikativer Minimalpreis | ||
| Fondsvermögen *** | 67'925'619 | |
| Anteilsklassevermögen *** | 1'121'606 | |
| Trading Information SIX | ||
| YTD-Performance | - | - |
|---|---|---|
| 1 Monat | -0.01% |
23.09.2025 - 23.10.2025
23.09.2025 23.10.2025 |
| 3 Monate | +0.20% |
23.07.2025 - 23.10.2025
23.07.2025 23.10.2025 |
| 6 Monate | +0.18% |
07.07.2025 - 23.10.2025
07.07.2025 23.10.2025 |
| 1 Jahr | - | - |
| 2 Jahre | - | - |
| 3 Jahre | - | - |
| 5 Jahre | - | - |
| Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aurium Clo VII Designated Activity Company | 3.76% | |
|---|---|---|
| Dryden 66 Euro Clo 2018 Designated Activity Company | 3.75% | |
| Blackrock European CLO XII Designated Activity Company | 3.75% | |
| ANCHORAGE CAPITAL EUROPE CLO | 3.75% | |
| Anchorage Capital Europe Clo 2 Designated Activity Company | 3.52% | |
| Avoca CLO XXXIII Designated Activity Co. | 3.30% | |
| CVC Cordatus Loan Fund V DAC | 3.29% | |
| AURIUM CLO | 2.82% | |
| Carlyle EURO CLO 2013-1 DAC | 2.82% | |
| Bain Capital Euro WH Cambridge Designated Activity Company | 2.82% | |
| Letzte Daten-Aktualisierung | 21.10.2025 | |
| TER | |
|---|---|
| Datum TER | |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.38% |
| Ongoing Charges *** | 0.28% |
|
SRRI ***
|
|
| Datum SRRI *** | |